Evidence map›Paper›PMID 31277334›Full record

ArticleMolecules (Basel, Switzerland)2019

New HSV-1 Anti-Viral 1'-Homocarbocyclic Nucleoside Analogs with an Optically Active Substituted Bicyclo[2.2.1]Heptane Fragment as a Glycoside Moiety.

Constantin I Tănase, Constantin Drăghici, Anamaria Hanganu, Lucia Pintilie, Maria Maganu, Alexandrina Volobueva, Ekaterina Sinegubova, Vladimir V Zarubaev, Johan Neyts, Dirk Jochmans and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Novel 1'-homo-RSC advances · 2020
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Constantin I TănaseNational Institute for Chemical-Pharmaceutical Research and Development, Department of bioactive substances and pharmaceutical technologies, 112 Vitan Av., 031299 Bucharest-3, Romania. cvtanase@gmail.com.
Constantin DrăghiciOrganic Chemistry Center "C.D.Nenitescu", Spectroscopy Laboratory, 202 B Splaiul Independentei, 060023 Bucharest, Romania.
Anamaria HanganuOrganic Chemistry Center "C.D.Nenitescu", Spectroscopy Laboratory, 202 B Splaiul Independentei, 060023 Bucharest, Romania.
Lucia PintilieNational Institute for Chemical-Pharmaceutical Research and Development, Department of bioactive substances and pharmaceutical technologies, 112 Vitan Av., 031299 Bucharest-3, Romania.
Maria MaganuOrganic Chemistry Center "C.D.Nenitescu", Spectroscopy Laboratory, 202 B Splaiul Independentei, 060023 Bucharest, Romania.
Alexandrina VolobuevaDepartment of Virology, Pasteur Institute of Epidemiology and Microbiology, 197101 St. Petersburg, Russia.
Ekaterina SinegubovaDepartment of Virology, Pasteur Institute of Epidemiology and Microbiology, 197101 St. Petersburg, Russia.
Vladimir V ZarubaevDepartment of Virology, Pasteur Institute of Epidemiology and Microbiology, 197101 St. Petersburg, Russia.
Johan NeytsKU Leuven Department of Micobiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49, BE-3000 Leuven, Belgium.
Dirk JochmansKU Leuven Department of Micobiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49, BE-3000 Leuven, Belgium.
Alexander V SlitaKU Leuven Department of Micobiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49, BE-3000 Leuven, Belgium.
Rega Institute for Medical Research · BESaint Petersburg Pasteur Institute · RUNational Institute For Chemical Pharmaceutical Research and Development · RO

Funding

Romanian Ministry for Research and Innovations PN 19-41 01 03/34N/2009; Aditional act 2/2019
6 · The paper itself

Abstract

New 1'-homocarbanucleoside analogs with an optically active substituted bicyclo[2.2.1]heptane skeleton as sugar moiety were synthesized. The pyrimidine analogs with uracil, 5-fluorouracil, thymine and cytosine and key intermediate with 6-chloropurine (

Indexed as

Antiviral AgentsDrug DesignGlycosidesHeptanesHumansLigandsMicrobial Sensitivity TestsMolecular ConformationMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureNucleosidesPurinesSpectrum AnalysisStructure-Activity RelationshipSugars6-chloropurineAntiviral AgentsGlycosidesHeptanesLigandsNucleosidesPurinesSugars1′-homocarbonucleosides6-chloropurine6-substituted adenine nucleosidesantiviral activitybicyclo[2.2.1]heptane nucleosidesherpesvirusesmolecular docking.

Identifiers

PMID31277334
PMCPMC6651170
OpenAlexW2953833629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.